<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03648437</url>
  </required_header>
  <id_info>
    <org_study_id>38/2018</org_study_id>
    <nct_id>NCT03648437</nct_id>
  </id_info>
  <brief_title>Paracetamol And Ibuprofen/Indomethacin in Closing Patent Ductus Arteriosus</brief_title>
  <acronym>PAI</acronym>
  <official_title>Paracetamol And Ibuprofen/Indomethacin in Closing Patent Ductus Arteriosus of Preterm Infants - Randomised, Placebo-controlled Multicentre Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oulu</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Helsinki University Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Turku University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tartu University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Oulu</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this pilot trial is to study efficacy and safety of simultaneous intravenous
      (iv) ibuprofen/indomethacin and paracetamol medications in the closure of patent ductus
      arteriosus (PDA) in preterm infants. It is randomized, placebo-controlled, double-blind,
      phase 1, multicenter, clinical trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Premature infants (born before 37 weeks gestational age) with patent ductus arteriosus (PDA)
      are the focus of the study since no trials on the additive efficacy of these two medications
      on the contraction of ductus arteriosus are available. Preterm infants who are diagnosed to
      have a hemodynamically significant PDA and who, according to the decision of the attending
      clinician, need ibuprofen/indomethacin therapy, are eligible to this trial.

      If the parents deny the consent, the patient will be treated according to the standard PDA
      treatment: three days' iv ibuprofen PedeaÂ® 5mg/ml solution infusion (Oulu, Helsinki, Tartu)
      dosing: 10mg/kg + 5mg/kg + 5mg/kg (q24h); or three days' iv indomethacin (Turku) 0.2mg/kg +
      0.1mg/kg + 0.1mg/kg (q24h). In case of any contraindications for ibuprofen/indomethacin, the
      treatment would be surgical ligation.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 3, 2018</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>multicenter, randomized, placebo-controlled, double-blind, clinical trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Placebo, 0.45 % saline, is similar to paracetamol, both being clear liquids, so the staff will remain unaware which drug the patient receives. The study drug will be kept and prepared away from the neonatal intensive care unit, at the separate ward 55 office, in a locked cabinet. The study drug will be prepared by the research nurse, the pharmacist of the ward, or during nighttime, by a nurse who does not participate in the study patients' treatment in any way.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Ductal closure</measure>
    <time_frame>Neonatal internsive care unit (NICU) stay up to 12 weeks</time_frame>
    <description>Number of patients with ductal contraction without need for other PDA therapies</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Need for ductal therapies</measure>
    <time_frame>NICU stay up to 12 weeks</time_frame>
    <description>Given ductal therapies after the study drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac ultrasound findings</measure>
    <time_frame>NICU stay up to 12 weeks</time_frame>
    <description>Ductal caliber (mm, mm/kg), LA/Ao ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of any ventilation assist</measure>
    <time_frame>NICU stay up to 12 weeks</time_frame>
    <description>The ventilation assist time pediod</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Paracetamol serum levels</measure>
    <time_frame>Study drug period up to 4 days</time_frame>
    <description>Measured paracetamol concentrations (mg/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Paracetamol side effects</measure>
    <time_frame>Study drug period plus 7 days, up to 10 days</time_frame>
    <description>Observed adverse events linked to study drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long term complications of prematurity</measure>
    <time_frame>Hospital stay up to 18 weeks</time_frame>
    <description>Moderate-to-severe bronchopulmonary dysplasia, intraventricular hemorrhage grade 2-4, moderate to severe necrotizing enterocolitis, retinopathy of prematurity needing therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other long-term morbidity, and mortality</measure>
    <time_frame>Hospital stay up to 18 weeks</time_frame>
    <description>Other severe diseases</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Patent Ductus Arteriosus</condition>
  <arm_group>
    <arm_group_label>Pedea 5mg/mL and Paracetamol 10mg/mL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous (IV) ibuprofen 5mg/mL q 24h for 3 days, dosages: 10mg/kg + 5mg/kg + 5mg/kg and IV paracetamol 10mg/mL for 3 days: loading dose 20mg/kg, following 7.5mg/kg q 6h (up to12 doses)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pedea 5mg/mL and 0.45 sodium chloride</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>IV ibuprofen 5mg/mL q 24h for 3 days, dosages: 10mg/kg + 5mg/kg + 5mg/kg and NaCl 0.45% for 3 days, the same amount in mL as would have been given IV paracetamol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Indomethacin 25mg/mL and Paracetamol10mg/mL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous (IV) indometahcin 25mg/mL q 24h for 3 days, dosages: 0.2mg/kg + 0.1mg/kg + 0.1mg/kg and IV paracetamol 10mg/mL for 3 days: loading dose 20mg/kg, following 7.5mg/kg q 6h (up to12 doses)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Indomethacin 25mg/mL and 0.45 sodium chloride</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intravenous (IV) indomethacin 25mg/mL q 24h for 3 days, dosages: 0.2mg/kg + 0.1mg/kg + 0.1mg/kg and NaCl 0.45% for 3 days, the same amount in mL as would have been given IV paracetamol</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paracetamol 10Mg/mL</intervention_name>
    <description>Experimental drug</description>
    <arm_group_label>Indomethacin 25mg/mL and Paracetamol10mg/mL</arm_group_label>
    <arm_group_label>Pedea 5mg/mL and Paracetamol 10mg/mL</arm_group_label>
    <other_name>Paracetamol Fresenius Kabi 10mg/mL infusion solution</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.45% Sodium Chloride</intervention_name>
    <description>Placebo comparator</description>
    <arm_group_label>Indomethacin 25mg/mL and 0.45 sodium chloride</arm_group_label>
    <arm_group_label>Pedea 5mg/mL and 0.45 sodium chloride</arm_group_label>
    <other_name>NATRIUMKLORID BRAUN 4,5 mg/mL infusion solution</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibuprofen</intervention_name>
    <description>Standard therapy</description>
    <arm_group_label>Pedea 5mg/mL and 0.45 sodium chloride</arm_group_label>
    <arm_group_label>Pedea 5mg/mL and Paracetamol 10mg/mL</arm_group_label>
    <other_name>Pedea 5mg/mL injection solution</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Indomethacin</intervention_name>
    <description>Standard therapy</description>
    <arm_group_label>Indomethacin 25mg/mL and 0.45 sodium chloride</arm_group_label>
    <arm_group_label>Indomethacin 25mg/mL and Paracetamol10mg/mL</arm_group_label>
    <other_name>Liometacen 50mg/2mL injection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Preterm infants (born before 37+0 gestation weeks) who are diagnosed to have a
             hemodynamically significant PDA and who, according to the decision of the attending
             clinician, need ibuprofen therapy, are eligible to this trial.

        Exclusion Criteria:

          -  severe malformation or suspected chromosomal defect

          -  other very severe life-threatening disease (e.g. very severe birth asphyxia or
             persistent pulmonary hypertension, etc.)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>4 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Outi Aikio, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oulu Univerisity Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Outi Aikio, MD, PhD</last_name>
    <phone>+35883155810</phone>
    <email>outi.aikio@ppshp.fi</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Aliisa Laitala, MD</last_name>
    <phone>+35883155823</phone>
    <email>aliisa.laitala@ppshp.fi</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Tartu University Hospital</name>
      <address>
        <city>Tartu</city>
        <country>Estonia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tuuli Metsvaht, MD, PhD</last_name>
      <phone>+37253319550</phone>
      <email>tuuli.metsvaht@kliinikum.ee</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Helsinki Univeristy Central Hospital</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Department of Pediatrics, Oulu University Hospital</name>
      <address>
        <city>Oulu</city>
        <zip>90014</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Outi Aikio, MD, PhD</last_name>
      <phone>+358 8 3155810</phone>
      <email>outi.aikio@ppshp.fi</email>
    </contact>
    <investigator>
      <last_name>Outi Aikio, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Antti Harma, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Timo Saarela, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mikko Hallman, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aliisa Laitala, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Turku University Hospital</name>
      <address>
        <city>Turku</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hanna Soukka, MD, PhD</last_name>
      <phone>+358415053930</phone>
      <email>hanna.soukka@utu.fi</email>
    </contact>
  </location>
  <location_countries>
    <country>Estonia</country>
    <country>Finland</country>
  </location_countries>
  <link>
    <url>http://jultika.oulu.fi/Record/isbn978-952-62-2524-1</url>
    <description>Thesis, Sanna JuujÃ¤rvi, MB</description>
  </link>
  <link>
    <url>http://jultika.oulu.fi/Record/isbn978-952-62-2025-3</url>
    <description>Thesis, Pia HÃ¤rkin, MD</description>
  </link>
  <reference>
    <citation>HÃ¤rkin P, HÃ¤rmÃ¤ A, Aikio O, Valkama M, Leskinen M, Saarela T, Hallman M. Paracetamol Accelerates Closure of the Ductus Arteriosus after Premature Birth: A Randomized Trial. J Pediatr. 2016 Oct;177:72-77.e2. doi: 10.1016/j.jpeds.2016.04.066. Epub 2016 May 20.</citation>
    <PMID>27215779</PMID>
  </reference>
  <reference>
    <citation>JuujÃ¤rvi S, Saarela T, Hallman M, Aikio O. Intravenous paracetamol was associated with closure of the ductus arteriosus in extremely premature infants. Acta Paediatr. 2018 Apr;107(4):605-610. doi: 10.1111/apa.14137. Epub 2017 Nov 17.</citation>
    <PMID>29105147</PMID>
  </reference>
  <reference>
    <citation>HÃ¤rmÃ¤ A, Aikio O, Hallman M, Saarela T. Intravenous Paracetamol Decreases Requirements of Morphine in Very Preterm Infants. J Pediatr. 2016 Jan;168:36-40. doi: 10.1016/j.jpeds.2015.08.003. Epub 2015 Aug 29.</citation>
    <PMID>26323200</PMID>
  </reference>
  <reference>
    <citation>Aikio O, HÃ¤rkin P, Saarela T, Hallman M. Early paracetamol treatment associated with lowered risk of persistent ductus arteriosus in very preterm infants. J Matern Fetal Neonatal Med. 2014 Aug;27(12):1252-6. doi: 10.3109/14767058.2013.854327. Epub 2013 Oct 31.</citation>
    <PMID>24111688</PMID>
  </reference>
  <reference>
    <citation>JuujÃ¤rvi S, Kallankari H, PÃ¤tsi P, Leskinen M, Saarela T, Hallman M, Aikio O. Follow-up study of the early, randomised paracetamol trial to preterm infants, found no adverse reactions at the two-years corrected age. Acta Paediatr. 2019 Mar;108(3):452-458. doi: 10.1111/apa.14614. Epub 2018 Nov 12.</citation>
    <PMID>30325529</PMID>
  </reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>August 23, 2018</study_first_submitted>
  <study_first_submitted_qc>August 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 27, 2018</study_first_posted>
  <last_update_submitted>March 25, 2020</last_update_submitted>
  <last_update_submitted_qc>March 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Oulu</investigator_affiliation>
    <investigator_full_name>Outi Aikio</investigator_full_name>
    <investigator_title>MD, PhD, Specialist in Peditrics and Neonatology</investigator_title>
  </responsible_party>
  <keyword>acetaminophen</keyword>
  <keyword>ibuprofen</keyword>
  <keyword>preterm infant</keyword>
  <keyword>near infra-red spectroscopy</keyword>
  <keyword>indomethacin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ductus Arteriosus, Patent</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Ibuprofen</mesh_term>
    <mesh_term>Indomethacin</mesh_term>
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 29, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/37/NCT03648437/Prot_SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

